Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

Alto Neuroscience Inc

ANRO
3,16
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:47:15
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/3/202514:00PRNUSChristopher Nixon Cox Named Chairman of High-Trend..
25/2/202514:03BWAlto Neuroscience to Participate in Upcoming Investor..
19/2/202514:03BWAlto Neuroscience Announces U.S. Patent Granted Covering..
12/2/202514:16EDGAR2Form 8-K - Current report
12/2/202514:03BWAlto Neuroscience Announces Favorable Outcome from Interim..
12/2/202506:15EDGAR2Form EFFECT - Notice of Effectiveness
07/2/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202522:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202522:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202522:39EDGAR2Form 8-K - Current report
03/2/202522:07EDGAR2Form S-3 - Registration statement under Securities Act of..
16/1/202513:00EDGAR2Form 8-K - Current report
06/1/202522:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202414:03BWAlto Neuroscience Announces Data Presented at the 63rd..
14/11/202413:00EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
12/11/202422:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:20EDGAR2Form 8-K - Current report
12/11/202422:10BWAlto Neuroscience Reports Third Quarter 2024 Financial..
08/11/202420:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
04/11/202414:00BWAlto Neuroscience to Participate in Upcoming Investor..
22/10/202422:35EDGAR2Form 8-K - Current report
22/10/202422:30BWAlto Neuroscience Reports Topline Results from a Phase 2b..
04/9/202414:05BWAlto Neuroscience Announces Peer-Reviewed Publication in the..
03/9/202414:05BWAlto Neuroscience to Participate in Upcoming Investor..
13/8/202422:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202422:33EDGAR2Form 8-K - Current report
13/8/202422:05BWAlto Neuroscience Reports Second Quarter 2024 Financial..
29/7/202422:19EDGAR2Form 8-K - Current report
25/7/202414:30BWAlto Neuroscience Receives Funding Award from Wellcome Trust..
16/7/202413:30BWAlto Neuroscience Announces Enrollment Completion in Phase..
11/7/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/6/202414:05BWAlto Neuroscience Initiates Phase 2 Study of ALTO-101, a..
18/6/202414:05BWAmit Etkin, M.D., Ph.D., Founder and CEO of Alto..
29/5/202414:05BWAlto Neuroscience to Present at the Jefferies Global..
21/5/202414:29EDGAR2Form 8-K - Current report
21/5/202414:05BWAlto Neuroscience Appoints Michael Hanley as Chief Operating..
14/5/202422:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:25EDGAR2Form 8-K - Current report
14/5/202422:03BWAlto Neuroscience Reports First Quarter 2024 Financial..
09/5/202414:05BWAlto Neuroscience Announces Data Presentations Highlighting..
23/4/202414:05BWAlto Neuroscience Announces Positive Phase 1 Results for..
03/4/202414:05BWAlto Neuroscience Announces Initiation of Phase 2 Study of..
21/3/202421:05BWAlto Neuroscience Reports Full Year 2023 Financial Results..
Apertura: Min: Max:
Chiusura: 3,16

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network